¹⁷⁷Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry.

Saturation of PSMA with a large excess of unlabeled compound causes a highly significant (p< 5 x 10 -6 ) reduction of binding of each labeled compound to cells, which demonstrates the saturable character of their binding ( Figure 3 ). 3.3.

also in 132,142 other papers